CCP
PFE icon

Corient Capital Partners’s Pfizer PFE Stock Holding History

Corient Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$6.08M Hold
116,005
– – 0.46% 50
2022
Q2 		$6.08M Buy
116,005
+15,715
+16% +$801K 0.46% 52
2022
Q1 		$5.19M Buy
100,290
+8,928
+10% +$463K 0.34% 67
2021
Q4 		$5.39M Buy
91,362
+4,281
+5% +$212K 0.36% 64
2021
Q3 		$3.75M Buy
87,081
+4,434
+5% +$196K 0.27% 85
2021
Q2 		$3.24M Buy
82,647
+6,482
+9% +$252K 0.24% 93
2021
Q1 		$2.76M Sell
76,165
-8,146
-10% -$289K 0.24% 87
2020
Q4 		$3.1M Sell
84,311
-4,051
-5% -$149K 0.31% 79
2020
Q3 		$3.08M Buy
88,362
+9,000
+11% +$316K 0.35% 69
2020
Q2 		$2.46M Sell
79,362
-28,496
-26% -$968K 0.3% 80
2020
Q1 		$3.34M Sell
107,858
-13,578
-11% -$463K 0.53% 49
2019
Q4 		$4.51M Sell
121,436
-2,073
-2% -$73.8K 0.57% 38
2019
Q3 		$4.21M Buy
123,509
+22,766
+23% +$828K 0.6% 38
2019
Q2 		$4.14M Buy
100,743
+11,920
+13% +$473K 0.63% 32
2019
Q1 		$3.58M Buy
88,823
+1,552
+2% +$62.2K 0.58% 33
2018
Q4 		$3.61M Buy
87,271
+21,908
+34% +$909K 0.64% 29
2018
Q3 		$2.73M Hold
65,363
– – 0.45% 63
2018
Q2 		$2.25M Buy
65,363
+24,750
+61% +$846K 0.39% 90
2018
Q1 		$1.37M Sell
40,613
-135
-0.3% -$4.64K 0.25% 102
2017
Q4 		$1.4M Buy
40,748
+3,041
+8% +$104K 0.24% 102
2017
Q3 		$1.28M Sell
37,707
-6,476
-15% -$208K 0.24% 100
2017
Q2 		$1.41M Buy
44,183
+2,067
+5% +$65.2K 0.22% 114
2017
Q1 		$1.37M Sell
42,116
-2,056
-5% -$64.8K 0.21% 111
2016
Q4 		$1.36M Sell
44,172
-2,900
-6% -$88.5K 0.24% 106
2016
Q3 		$1.51M Buy
+47,072
New +$1.57M 0.28% 98

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Corient Capital Partners's PFE Position: Q3 2022 in Review

Corient Capital Partners held its Pfizer (PFE) position steady in Q3 2022 at 116,005 shares worth $6.08M. The position accounts for 0.46% of the portfolio, ranked #50.

Corient Capital Partners first reported a position in PFE in Q3 2016 and has held it in 25 quarters since. 3,088 funds tracked by Wall St. Rank hold PFE as of Q3 2022.

  • Corient Capital Partners held 116,005 shares of Pfizer worth $6.08M as of Q3 2022.
  • Corient Capital Partners left its Pfizer share count unchanged in Q3 2022.
  • Pfizer made up 0.46% of Corient Capital Partners's portfolio in Q3 2022, its #50 holding.
  • Corient Capital Partners first reported a position in Pfizer in Q3 2016 and has held it in 25 quarters since.
  • 3,088 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.